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Background and objective: Dietary intake of fruits and vegetables has been suggested to have a role in pro-
moting bone health. More speciﬁcally, the polyphenols they contain have been linked to physiological effects
related to bone mineral density and bone metabolism. In this research, we use standard microarray analyses
of peripheral whole blood from post-menopausal women treated with two ﬁxed combinations of plant ex-
tracts standardized to polyphenol content to identify differentially expressed genes relevant to bone health.
Methods: In this 28-day open-label study, healthy post-menopausal women were randomized into three
groups, each receiving one of three investigational ﬁxed combinations of plant extracts: an anti-resorptive
(AR) combination of pomegranate fruit (Punica granatum L.) and grape seed (Vitis vinifera L.) extracts; a bone
formation (BF) combination of quercetin (Dimorphandra mollis Benth) and licorice (Glycyrrhiza glabra L.) ex-
tracts; and a ﬁxed combination of all four plant extracts (AR plus BF). Standard microarray analysis was per-
formed on peripheral whole blood samples taken before and after each treatment. Annotated genes were
analyzed for their association to bone health by comparison to a gene library.
Results: The AR combination down-regulated a number of genes involved in reduction of bone resorption
including cathepsin G (CTSG) and tachykinin receptor 1 (TACR1). The AR combination also up-regulated
genes associated with formation of extracellular matrix including heparan sulfate proteoglycan 2 (HSPG2)
and hyaluronoglucosaminidase 1 (HYAL1). In contrast, treatment with the BF combination resulted in up-
regulation of bone morphogenetic protein 2 (BMP-2) and COL1A1 (collagen type I α1) genes which are linked
to bone and collagen formation while down-regulating genes linked to osteoclastogenesis. Treatment with a
combination of all four plant extracts had a distinctly different effect on gene expression than the results of
the AR and BF combinations individually. These results could be due to multiple feedback systems balancing
activities of osteoblasts and osteoclasts.
Conclusion: In summary, this ex-vivomicroarray study indicated that the pomegranate, grape seed, quercetin
and licorice combinations of plant extracts modulated gene expression for both osteoclastic and osteogenic
processes.
© 2015 The Authors. Published by Elsevier GmbH.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Abbreviations: A, osteoarthritis; AR, anti-resorptive ﬁxed combinations of plant ex-
tracts; BF, bone formation ﬁxed combinations of plant extracts; BMI, body mass index;
BMP-2, bone morphogenetic protein 2; C, combination of all four plant extracts; DEXA,
dual-energy x-ray absorptiometry; DM, diabetes miletus type 2; ETOH, ethanol; HC,
hypercholesterolemia; HT, hypertension; RANKL, receptor activator of nuclear factor
kappa-B ligand.
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design, research; data analysis, and preparation of the report. Yumei Lin had primary
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Bone is a dynamic tissue constantly in a cycle of resorption and
ormation. Established bone is degraded by osteoclasts through ad-
erence, acidiﬁcation, and proteolytic digestion; then, osteoblasts
uild bone in the excavated sites by excreting osteoid which miner-
lizes to become new bone. Bone remodeling renews approximately
0% of bone each year, resulting in an entirely new skeleton roughly
very 7 to 10 years (Post et al. 2010). Bone mass changes with age,E-mail address: kevin.gellenbeck@amway.com (K.W. Gellenbeck).
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Tablet dose of botanical extract combinations for each treatment group.
Group Total daily dose
Anti-Resorptive (AR) 500 mg ellagic acid (from 1250 mg pomegranate) and
50 mg total polyphenol (from 125 mg grape seed
extract) in 3 tablets.
Bone Formation (BF) 215 mg quercetin (from 250 mg quercetin extract) and
0.0625 mg glabridin (from 125 mg licorice extract)
in 2 tablets.
Combination (C) 500 mg ellagic acid (from 1250 mg pomegranate) and
50 mg total polyphenol (from 125 mg grape seed
extract) and 215 mg quercetin (from 250 mg
quercetin extract) and 0.0625 mg glabridin (from
125 mg licorice extract) in 4 tablets.
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Reaking in adults aged 20 to 30 years and declining after age 50. The
oss of bonemass associatedwith aging can result in an increased risk
f fracture and osteoporosis (Habauzit and Horcajada 2008).
According to the National Health and Nutrition Examination Sur-
eys, the predominate treatment for osteoporosis in the 1988–1994
urvey was estrogen, while in the 2005-2006 survey it was almost
xclusively bisphosphonates (Looker et al. 2010). In addition to med-
cations, nutritional research on bone health indicates the impor-
ance of an adequate intake of dietary calcium, vitamin D, and pro-
ein. Research into the correlation between fruit and vegetable intake
nd bone mineral density has suggested a role for the polyphenolic
ompounds found in fruits and vegetables in promoting bone health
Habauzit and Horcajada 2008).
Using a targeted series of in vitro and in vivo assays, we have
ecently identiﬁed two botanical extract combinations which af-
ect bone resorption or formation (Lin et al. 2014). One is an anti-
esorptive combination of pomegranate fruit and grape seed ex-
racts that was shown to maintain bone mass by preventing calcium
oss through its ability to inhibit the expression of receptor activa-
or of nuclear factor kappa-B ligand (RANKL), a cytokine of the tu-
or necrosis factor family involved in osteoclast differentiation. The
ther, a combination of quercetin and licorice extracts, was shown to
aintain maximum bone mass by stimulating bone formation and
nhancing calcium deposition through activation of bone morpho-
enetic protein 2 (BMP-2), a member of the transforming growth fac-
or beta family known to stimulate bone production (Lin et al. 2014).
Ideally, the next step would be to evaluate the eﬃcacy of these
otanical extract combinations on bone health in a human clinical
tudy. The most direct end-point in such clinical trials is a mea-
urement of bone mineral density using dual-energy x-ray absorp-
iometry (DEXA). However, due to the slow rate of bone turnover in
umans, this type of study requires a long intervention period and
large sample size. To reduce these factors, an alternate analysis
ould be to quantitate the effects of the botanical extract combi-
ations on bone turnover biomarkers such as speciﬁc alkaline phos-
hatase, serum osteocalcin, serum C-terminal cross-linked telopep-
ides of type I collagen, and urinary osteocalcin. Quantifying these
arkers is safe and easy to perform compared to DEXA or other imag-
ng techniques, however, the use of these biomarkers is not withoutTable 2
Botanical extract preparations.
Common name Manufacturer Genus/Species Plant part
Pomegranate Polinat Punica granatum L.
(Lythraceae)
Dry fruit
Grape Polyphenolics Vitis vinifera L. (Vitaceae) Dry seed
Fava d’anta PVP Sociedade
Anonima
Dimorphandra mollis Benth.
(Leguminosae)
Dry fruit
Licorice Access Business
Group
Glycyrrhiza glabra L.
(Leguminosae)
Dry rhizom
∗ Minimum speciﬁcations.ontroversy due to individual variability and the complexity of bone
etabolism (Vasikaran 2008).
An alternative to both of these approaches is to use microarray
echnology to directly evaluate the effect of botanical extracts on
olecularmechanisms affecting bonemetabolism.Microarray analy-
is is a potentially valuable tool due to its sensitivity and the increas-
ng ability to correlate changes in gene expression with biomarkers
nd functional activity. Microarray analyses of circulating monocytes
Dvornyk et al. 2007; Lei et al. 2009; Liu et al. 2005) and B cells (Xiao
t al. 2008) extracted from peripheral whole blood in humans with
ow and high bone mass has been used to identify differentially ex-
ressed genes involved in bone metabolism. In this research, we use
tandard microarray analyses of peripheral whole blood, which in-
ludes monocytes and B cells, from post-menopausal women treated
ith our anti-resorptive and bone building botanical extract combi-
ations, to identify differentially expressed genes relevant to bone
ealth through comparison to a gene library.
aterials and methods
otanical extracts and test combinations
The composition of the three investigational combinations, an
nti-resorptive combination (AR), a bone formation combination
BF), and a combination of all four plant extracts (C), is described
n Table 1, and the sources and speciﬁcations for the botanical ex-
racts are provided in Table 2. All the extracts are acceptable for use
n nutritional supplements in the USA where the study was com-
leted. Botanical authentication was provided by the manufacturers
or the purchased extracts, and for the licorice was veriﬁed by chain
f custody from seed at the Access Business Group Farm. Dosages
ere determined from analysis of the previous in vitro and in vivo
ata (Lin et al. 2014) and was converted from rat to human body size
nd blood volumes using the FDA Human Equivalent Dose conversion
ormula. The quality and standardization of the extracts were previ-
usly described in detail in Fast et al. (2013). Brieﬂy, all extracts ex-
ept for licorice were obtained from commercial suppliers and each
uaranteed for phytochemical standardization by Certiﬁcate of Anal-
sis from the supplier. In addition, all the extracts usedwere analyzed
uantitatively and qualitatively and veriﬁed using the appropriate an-
lytical methods. Method details and resulting chromatograms are
xcerpted from Fast et al. (2013) and included in the supplemental
aterials (e-component).
ubjects and study design
This was a 28-day, open-label study in which 46 healthy post-
enopausal womenwere randomized into three groups, each receiv-
ng one of three investigational combinations. All test combinations
ere in tablet form with microcrystalline cellulose as a carrier. The
ablets were manufactured in a Good Manufacturing Practices certi-
ed facility.
The study subjects were obtained through the Southbay Pharma
esearch (Buena Park, CA) population pool which is approximatelyStandardization∗ Drug Extract Ratio/Solvent Excipient
40% ellagic acid 40:1/70 % ethanol None
40% total polyphenols 40:1/water 50% maltodextrin
86% quercetin 15:1/ethanol None
e 0.05% glabridin 6:1/70% ethanol 25% maltodextrin
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u40% Caucasian, 20% Hispanic, 30% Asian/Paciﬁc Islander and 10%
other ethnicities. The selected subjects were non-smoking post-
menopausal (6 months to 5 years after the beginning of menopause)
women aged 45 to 62 years old. All participantswere required to be in
good general health as assessed via interview and abbreviated phys-
ical examination. Subjects with stable medical conditions and who
followed a consistent medication regimen with proper medical su-
pervisionwere eligible. For the duration of the trial, participants were
instructed to maintain their exercise habits and current diet, with the
exception of not consuming pomegranates, foods high in quercetin
(e.g., apples and onions), licorice, or supplements containing grape
seed extract.
Subjects were excluded from study participation for any of the
following conditions: cigarette smoker or history of tobacco use
within the past year; use of dietary supplements (vitamins, miner-
als, and herbal formulas, including herbal drinks) within one week
of the beginning of the study; the presence of osteoporosis, cancer,
or other unstable health conditions; participation in another clinical
trial within 30 days of enrollment into the study; history of or cur-
rent drug or alcohol abuse; known allergy to the botanical test com-
binations; a change in hormone therapy (including oral contracep-
tives) within 4 weeks prior to the beginning of the study or expected
change during the study; or any condition that the Principal Investi-
gator thought would put the subject at undue risk.
This study was conducted at Southbay Pharma Research in accor-
dance with the guidelines for current Good Clinical Practice, the Dec-
laration of Helsinki (1996), and US Code of Federal Regulations (Title
21, Part 50 Protection of Human Subjects). All subjects provided full
informed consent and the study protocol was approved by the Alpha
IRB (San Clemente, CA).
On study Day 1, subjects were enrolled, interviewed as to compli-
ance with the inclusion and exclusion criteria, and written informed
consent obtained. A medical history was taken, a medical exam per-
formed, and fasting samples (overnight or a minimum of 8 hours)
of urine and blood were obtained. The subjects were randomized to
the study groups, given a 2-week supply of test combinations, and
instructed to take the tablets according to directions printed on the
bottle. It was recommended that all tablets be taken at the same time
each day, in the morning, with breakfast.
On Day 2, participants were interviewed by phone and any par-
ticipants found to have abnormal serum chemistry, hematology, or
urinalysis were dismissed from the study. On Day 14, study compli-
ance was assessed at the clinic through interviews and collection of
any unused tablets. Subjects were questioned about adverse events
or any unusual signs or symptoms. An additional 2-week supply of
tablets was dispensed. On Day 28, participants returned to the clinic
for assessment of compliance, questioned regarding adverse events,
and fasting samples of blood and urine were obtained. Compliance
with study tablet administration was recorded as a percentage of the
actual intake to total scheduled intake. Non-compliance was deﬁned
as consumption of less than 80% of scheduled intake.
Subjects were requested to report any adverse events that oc-
curred during the course of the study. Safety and tolerability were
also monitored via serum chemistry, hematology, urinalysis, and vi-
tal signs taken on study Day 1 and 28.
Microarray analysis
The effects of each ﬁxed combination of plant extracts were de-
termined by comparing gene expression proﬁling data between Day
1 (baseline) and end of treatment on Day 28. Fasting blood samples
(approximately 2.5 ml) were collected in PAXgene blood RNA tubes
and stored at 4 ºC for no longer than ﬁve days before being shipped to
Ocimum Biosolutions, LLC (Houston, TX), for microarray analysis.
The blood samples were analyzed for distribution of periph-
eral blood mononuclear cells and samples with similar distributionurves were selected for analysis. Ten samples from each treatment
roup underwent microarray analysis.
Total RNA was extracted using a Qiagen RNeasy Mini Kit per
anufacturer’s instructions and its quality determined with an Ag-
lent 2100 Bioanalyzer RNA 6000 Nano LabChip Kit. Microarray as-
essments were performed according to the Agilent One-Color Hu-
an 4 × 44 K Gene Expression Microarray protocol. Brieﬂy, total
NA (500 ng) was ampliﬁed and labeled using the One-color Quick
mp labeling kit (Agilent Technologies, Santa Clara, CA, USA). Labeled
RNA was puriﬁed using Qiagen RNeasy spin columns and the quan-
ity and quality of the cRNA was determined using a Nanodrop ND-
000 UV-VIS spectrophotometer. Using the Agilent Gene Expression
ybridization Kit, 1.65 μg of cRNA were hybridized onto a Human
× 44 K Gene Expression Microarray slide, sealed in a hybridiza-
ion chamber, and hybridized for 17 h, at 65 °C in a rotating oven.
he slides were then washed with wash buffer, scanned on an Agi-
ent Microarray Scanner, and data extraction and analysis performed
sing Feature Extraction software, version 9.5.3. Functionally anno-
ated genes (those linked to any metabolic processes) were further
nalyzed for their relationship to bone health by comparisonwith the
ene Logic BioExpress® gene expression database (Markowitz and
opaloglou 2001; Markowitz, et al. 2002; Scherf et al. 2000).
tatistical analysis
Quality control and statistical procedures were performed using
MP Genomics software (SAS Institute Inc., Cary, NC). The Maha-
anobis distance quality control (MDQC) procedure was applied to
dentify outlier arrays. Following the quality assessment, the datawas
rocessed with normalization and summarization to obtain ﬁnal ex-
ression values for each gene on the log2 scale. Loess normalization
rocedure was used to perform all these steps on probe-level data.
Statistics were calculated using one-way ANOVA followed by two-
ided t-test to determine treatment effect on gene expression. Sum-
ary statistics were performed using t-tests in conjunction with log-
old change to determine differentially expressed genes. The differen-
ially expressed geneswere identiﬁed as a level of signiﬁcanceα = 0.5
nd fold change ≥ 1.5. Signiﬁcance analysis of microarrays (SAM) was
sed to ensure that the false discovery rate was within 5%. Gene ex-
ression diagrams were prepared with Metacore Bioinformatics soft-
are from Thomson Reuters (https://portal.genego.com/).
esults
tudy participants
Eighty-four post-menopausal womenwere screened, and 46 were
nrolled and randomized into the three treatment groups. Of these
6 subjects, there were 7 Asians (15%), 10 African Americans (22%),
4 Caucasians (30%), and 15 Hispanics (33%). There were no signif-
cant differences between treatment groups in age, basal metabolic
ate (BMI, kg/m2), or duration from onset of menopause (Table 3).
ubjects with type 2 diabetes, hypercholesterolemia, hypertension,
steoarthritis, and rheumatoid arthritis were included in the study if
hey were cancer-free, in stable condition and followed a consistent
edication regimen with medical supervision, distribution of these
articipants are listed in Table 3. Of the enrolled participants, 43 com-
leted the study. No participants were discontinued from the study
ue to study treatment. The process of enrollment, intervention and
ample analysis is summarized in Fig. 1.
icroarray results
Microarray analysis indicated that 267, 880, and 219 genes were
p-regulated in the AR, BF, and C treatment groups, respectively. The
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Table 3
Subject characteristics.
Group n Age Years from onset of
menopause
BMI Number of subjects with speciﬁc
medical conditions
Mean SD Mean SD Mean SD DM HC HT A
AR 15 52.0 3.7 2.2 1.3 27.1 5.6 2 1 3 1
BF 15 52.8 5.8 3.3 1.3 30.8 7.5 2 1 4 1
C 16 55.6 6.0 2.8 1.4 31.2 8.0 1 3 5 3
BMI, body mass index; DM, diabetes miletus type 2; HC, hypercholesterolemia; HT, hypertension; A, osteoarthritis; AR,
anti-resorptive combination; BF, bone formation combination; C, all four ﬁxed combinations of plant extracts (AR + BF).
Fig. 1. Subject enrollment, intervention and sample analysis.
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aumber of down-regulated genes were 564, 2049, and 1340 in treat-
ent groups AR, BF and C, respectively. Functionally annotated genes
ere further analyzed for their relationship to bone metabolism.
nti-resorptive (AR) treatment group
The effect of the AR combination on expression of select anno-
ated genes related to bone metabolism is shown in Table 4; the fold-
hange from baseline for these differentially expressed genes was
igniﬁcant at the level of signiﬁcance α = 0.05. Up-regulated genes
ncluded heparan sulfate proteoglycan 2 (HSPG2), hyaluronoglu-
osaminidase 1 (HYAL1) and interleukin 7 (IL-7), and down-regulated
enes included interleukin 6 (IL-6), and C-reactive protein (CRP), as
ell as cathepsin G (CTSG), tachykinin receptor 1 (TACR1), chemokine
C-X3-C motif) ligand 1(CX3CL1), frizzled homolog 1 (FZD1), and
nsulin-like growth factor 2 (IGF2). The down-regulation of CTSG andACR1 is associated with down-regulation of RANKL activity, which
s implicated in bone resorption (Lin et al. 2014). A schematic sum-
arizing the effect of the AR combination on the expression of select
nnotated genes following 28 days of treatment is shown in Fig. 2.
one formation (BF) treatment group
The effect of the bone formation combination on expression of se-
ect annotated genes associated with osteogenesis is listed in Table 5.
MP-2, the biomarker used in our previous in vitro screening assay
4), was signiﬁcantly up-regulated by this combination as were colla-
en type Iα1(COL1A1), artemin (ARTN), neuromedin B (NMB), synde-
an 1 (SDC1), and cystatin SA (CST2). Similar to the effects seen with
he AR combination, IL-6 was also down-regulated. Other genes im-
ortant for enhancing osteoclastogenesis, CD200 receptor 1 (CD200),
ctivin A receptor type IIB (ACVR2B), toll-like receptor 4 (TLR4), and
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Table 4
The effect of the anti-resorptive combination on change of expression of select anno-
tated genes as measured by microarray.
Gene
symbol
Gene names, alternative abbreviations Fold
change∗
Direction
IL-6 Interleukin 6 (interferon, beta 2) 1.66 down
CRP C-reactive protein, pentraxin-related 1.53 down
IL-7 Interleukin 7 1.67 up
CX3CL1 Chemokine (C-X3-C motif) ligand 1 2.27 down
IGF2 Insulin-like growth factor 2
(somatomedin A)
2.02 down
FZD1 Frizzled homolog 1 (Drosophila) 2.12 down
TACR1 Tachykinin receptor 1, substance P
receptor
2.37 down
CTSG Cathepsin G 2.11 down
CD80 CD80 molecule 1.86 down
CD86 CD86 molecule 2.27 down
HYAL1 Hyaluronoglucosaminidase 1 1.5 up
HSPG2 Heparan sulfate proteoglycan 2
(Perlecan)
1.51 up
TNR Tenascin R (restrictin, janusin) 1.53 up
SPON1 Spondin 1, R-spondin1 extracellular
matrix protein
1.88 up
∗ Fold-change from baseline was signiﬁcant at p < 0.05.
Table 5
The effect of the bone forming combination on change of expression of select genes as
measured by microarray.
Gene
symbol
Gene names, alternative abbreviations Fold
change∗
Direction
IL1R1 Interleukin 1 receptor, type I 1.75 Down
IL-6 Interleukin 6 (interferon, beta 2) 1.66 Down
IL-8 Interleukin 8 1.72 Down
CD200 CD200 receptor 1 2.29 Down
ACVR2B Activin A receptor, type IIB, ActRIIB 2.67 Down
CTSO Cathepsin O 2.13 Down
TLR4 Toll-like receptor 4 2.16 Down
CMTM6 CKLF-like MARVEL transmembrane
domain containing 6
2.07 Down
AMH Anti-Mullerian hormone 2.49 Up
SDC1 Syndecan 1 1.62 Up
AVP Arginine vasopressin (Neurophysin-II,
antidiuretic hormone, diabetes
insipidus, neurohypophyseal)
2.47 Up
CST2 Cystatin SA 2.06 Up
NMB Neuromedin B 1.58 Up
BMP-2 Bone morphogenetic protein 2, BMP2 3.23 Up
COL1A1 Collagen type I α1 2.24 Up
COL5A1 Collagen type V α1 1.76 Up
TNXB Tenascin XB, tenascin-X 2 Up
THBS4 Thrombospondin 4 1.97 Up
COL4A2 Collagen type IV α2 1.84 Up
COL9A1 Collagen type IX α1 1.58 Up
ARTN Artemin 3.11 Up
∗ Fold-change from baseline was signiﬁcant at p < 0.05.
ﬁ
t
r
in osteoblast differentiation andmaturation. The combination all fourcathepsin O (CTSO) were also down-regulated following 28 day sup-
plementationwith the BF combination. Fig. 3 is a schematic represen-
tation of the change in expression of select annotated genes following
administration of the BF combination for 28 days.
Combination (C) of all four botanical extracts treatment group
The effect on gene expression of all four botanical extracts com-
bined is listed in Table 6. This combinaton was shown to up-regulateFig. 2. A representation of the effect of the anti-resorptive combination on gene expres
materials, e-component). Changes in the expression of select annotated genes in response to
CRP, C-reactive protein; IL-7, interleukin 7; CX3CL1, chemokine (C-X3-C motif) ligand 1; IGF2
tachykinin receptor 1; Cathepsin G; CD80, CD80 molecule; CD86, CD86 molecule; HYAL1,
R-spondin1.broblast growth factor 9 (FGF9), a secreted growth factor known
o have a critical role in angiogenesis and osteogenesis, and runt-
elated transcription factor 2 (RUNX2), a transcription factor involvedsion and bone formation. (Diagram object legend can be found in the supplemental
administration of the anti-resorptive (AR) combination for 28 days. IL-6, interleukin 6;
, insulin-like growth factor 2; FZD1, frizzled homolog 1; Substance P Receptor, TACR1,
hyaluronoglucosaminidase 1; Perlecan, heparan sulfate proteoglycan 2; Tenascin-R;
Y. Lin et al. / Phytomedicine 23 (2016) 18–26 23
Fig. 3. A representation of the effect of the bone formation combination on gene expression and bone formation. (Diagram object legend can be found in the supplemental
materials, e-component). Changes in the expression of select annotated genes in response to administration of the bone formation (BF) combination for 28 days. IL-1R1, interleukin
1 receptor type I; IL-6, interleukin 6; IL-8, interleukin 8; CD200, CD200 receptor 1; Cathepsin O; ActRIIB, activin A receptor type IIB; TLR4, toll-like receptor 4; CMTM6, CKLF-like
MARVEL transmembrane domain containing 6; COL1A1, collagen type I α1; COL5A1, collagen type V α1; TNXB, Tenascin-X; Thrombospondin 4; COL4A2, collagen type IV α2;
collagen type XXIII α1; COL9A1, collagen type IX α1; AMH, anti-Mullerian hormone; Syndecan-1; Neurophysin-II; Cystatin SA; ARTN, artemin; BMP2, bone morphogenetic protein
2; Neuromedin B.
Table 6
The effect of a combination of all four plant extracts (AR + BF) on change of expression
of select genes as measured by microarray.
Gene
symbol
Gene names, alternative abbreviations Fold
change∗
Direction
CXCL1 Chemokine (C-X-C motif) ligand 1
(melanoma growth stimulating
activity, alpha)
1.65 Down
TGFα Transforming growth factor, alpha,
TGF-alpha
1.73 Down
CXCL10 Chemokine (C-X-C motif) ligand 10,
IP10
1.57 Down
FASLG Fas ligand (TNF superfamily, member
6), FasL(TNFSF6)
1.61 Down
IL1RAP Interleukin 1 receptor accessory
protein
1.85 Down
RUNX2 Runt-related transcription factor 2 1.7 Up
FGF9 Fibroblast growth factor 9
(glia-activating factor)
1.69 Up
∗ Fold-change from baseline was signiﬁcant at p < 0.05.
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Table 7
Summary of adverse events.
Adverse event Treatment
group
Known medical condition(s)
Glucose, AST, ATL value above
normal range
AR Depression, hepatitis C
Glucose value above normal range,
CO2 value below normal range
AR Diabetes type 2
Glucose value above normal range BF Hypertension, osteoarthritis
Glucose value above normal range BF -
Glucose value above normal range BF -
WBC and platelet count below
normal range
BF -
Glucose value above normal range BF Diabetes type 2
Albumin value below normal range C Osteoarthritis
WBC count above normal range C -
Adverse events are those reported on study day 28; AST, aspartate aminotransferase;
ATL, alanine aminotransferase; WBC, white blood cell; AR, anti-resorptive combina-
tion; BF, bone formation combination; C, combination of all four plant extracts (AR +
BF).
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slant extracts (AR + BF) down-regulatedmediators of osteoclastogen-
sis such as transforming growth factor alpha (TGFα) and chemokine
C-X-C motif) ligand 10 (CXCL10) as well as chemokine (C-X-C motif)
igand 1 (CXCL1), a mediator of inﬂammation. Other select annotated
enes down-regulated following 28 day supplementation with the
ombination of all four extracts (AR + BF) were TNF receptor super-
amily member 6, FAS ligand (FASLG), and interleukin 1 receptor ac-
essory protein (IL1RAP). The results for the combination treatment
roup did not show an increase in BMP-2 gene expression despite an
ncrease following treatment with the BF combination alone, nor a
ecrease in CTSG and TACR1 gene expression as found in the treat-ent with AR combination alone. Fig. 4 is a schematic representa-
ion of the change in expression of select annotated genes following
dministration of the C combination of all four plant extracts for 28
ays.
afety and tolerability of the botanical extract combinations
No serious adverse events were reported for subjects in any of
he treatment groups. Nine of the 43 participants had biochemical
est results outside normal range on day 28 (Table 7). Six of these
howed blood glucose levels above normal range; two had previously
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Fig. 4. A representation of the effect of all four plant extracts combined (AR + BF) on gene expression and bone formation. (Diagram object legend can be found in the
supplemental materials, e-component). Changes in the expression of select annotated genes in response to administration of the combination (C) of all four plant extracts for 28
days. CXCL1, chemokine (C-X-Cmotif) ligand 1; TGF-alpha, transforming growth factor alpha; IP10, chemokine (C-X-Cmotif) ligand 10; FasL(TNFSF6), Fas ligand; IL1RAP, interleukin
1 receptor accessory protein; RUNX2, runt-related transcription factor 2; FGF9, ﬁbroblast growth factor 9.
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ndiagnosed type 2 diabetes, and four were in the BF treatment group.
None of the abnormal test results were determined by study physi-
cian to be due to study treatment. Overall, all three ﬁxed combina-
tions of botanical extracts were considered safe and well-tolerated
throughout the study period.
Discussion
Molecular genetic studies have linked a number of genes to osteo-
genesis and osteoporosis in human populations, laying a foundation
for our understanding of the mechanisms of gene expression under-
lying bone health. The most widely studied of these genes are the
vitamin D receptor, estrogen receptor, and LDL receptor-related pro-
tein 5. However, many other genes have also been identiﬁed as links
to bone health including genes for calciotropic hormones, cytokines,
growth factors, and bonematrix proteins (Markowitz et al. 2002). Re-
centmicroarray studies involving osteoporosis and related traits have
focused on regulation of osteoblast and osteoclast activity; differenti-
ation ofmesenchymal stem cells; comparison of healthy and diseased
tissues; the effects of therapeutic agents, and endocrine regulation
(Xu et al. 2010).
In this study, we examined the effect of two botanical extract com-
binations, separately and in combination, on gene expression in an
ex-vivomicroarray analysis ofmRNA obtained fromwhole blood sam-
ples of post-menopausal women treated for 28 days. The prepara-
tion and analysis include the monocytes and B cells which have been
shown to reﬂect inﬂuence on bone tissue. The botanical extract com-
binations were previously identiﬁed through in vitro assays for their
effects on RANKL or BMP-2 expression, and further tested by func-
tional studies in calvarial tissues and animal models (Lin et al. 2014),
providing a link between gene expression and functionality. In this
research, we identify differentially expressed genes linked to func-
tional activities related to bone metabolism.The interaction between receptor activator of nuclear factor
appa-B (RANK) and RANKL leads to the proliferation and activation
f osteoclasts. Therefore, the RANK-RANKL pathway for induction of
one resorption is a recognized target for therapeutic agents in the
reatment of osteoporosis (Deschaseaux et al. 2009; Teletchea et al.
014). The pomegranate and grape seed extracts in the AR combina-
ion inhibited RANKL expression in vitro (Lin et al. 2014) but no di-
ect change in RANKL expression was measured in this ex-vivo study.
owever, the microarray analysis did demonstrate that CTSG and
ACR1 were down-regulated in the AR treatment group, a process
hought to inhibit osteolysis by reducing RANKL production (Kojima
t al. 2006; Matayoshi et al. 2005; Steinhoff et al. 2014; Wang et al.
009; Wilson et al. 2008).
Genes up-regulated in the AR treatment group included HSPG2
nd HYAL1, proteins involved in extracellular matrix generation and
emodeling (Xu et al. 2010), and IL-7, a direct inhibitor of osteoclasto-
enesis (Gendron et al. 2008). Besides CTSG and TACR1, other genes
own-regulated in the AR treatment group included CX3CL1, FZD1
nd IGF2, associated proteins known to play a role in enhancing os-
eoclastogenesis (Xu et al. 2010), and IL-6 and CRP, mediators asso-
iated with inﬂammation (McLean 2009). IL-6 induces osteoclastic
recursor cell proliferation, and its inhibition is a suggested target for
he treatment of osteoporosis (Terpos et al. 2011). Increased levels of
RP, a general inﬂammation biomarker, are associated with a number
f disease conditions, but its role in osteoporosis is not clear. A co-
ort study with a follow-up period of 6 years reported that low CRP
evels were associated with reduced risk of osteoporotic fracture in
lderly Asian women (Nakamura et al. 2011). However, a population
ased study conducted in Iran concluded that subclinical systemic
nﬂammation may not be involved in loss of bone mass in healthy
ostmenopausal women (Nabipour et al. 2009).
Botanical extracts (quercetin and licorice extract) in the BF combi-
ationwere previously shown to increase expression of BMP-2mRNA
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Nnd protein, and to promote bone growth in cultured mouse cal-
ariae (Lin et al. 2014). BMP-2 gene expression was up-regulated in
his ex vivo human study following treatment with the BF combina-
ion. BMP-2 and BMP-4, members of the transforming growth fac-
or β family, have been established as crucial for the progression and
aturation of osteogenesis (Deschaseaux et al. 2009). Recombinant
uman BMP-2 has found clinical use in the treatment of fractures that
o not heal as expected (Garrison et al. 2010).
Microarray analyses of blood samples from the BF treatment
roup also show an increase in COL1A1 gene expression. Collagen
ype 1 is the most abundant protein in connective tissue and is es-
ential for normal bone function (Xu et al. 2010). The up-regulation of
OL1A1 indicates that collagen synthesis may be stimulated follow-
ng treatment with the BF combination. Other genes associated with
steoblastic and chondrocytic activities were also up-regulated in-
luding ARTN, NMB, SDC1, and CST2. Similar to treatment with the AR
ombination, IL-6 was down-regulated in the BF treatment group in-
icating a reduction in osteoclastic precursor cell proliferation. Other
enes important for enhancing osteoclastogenesis including CD200,
CVR2B, TLR4, and CTSO were also down-regulated in the BF treat-
ent group.
Treatment with the combination of all four plant extracts, the
treatment, increased expression of RUNX2, considered one of the
master genes’ for bone formation (Deschaseaux et al. 2009). FGF9
as also up-regulated by the combination of all four plant extracts
uggesting an increase in osteoblast proliferation and bone formation
Behr et al. 2010). Genes that were down-regulated in the C treat-
ent group included TGFα, a known stimulator of osteoclastic bone
esorption working with RANKL in the early stage of osteoclast differ-
ntiation (Fox et al. 2008); CXCL10, known to have a pathogenic role
n bone destruction and osteoclastogenesis possibly by mediating in-
reases in RANKL expression (Lee et al. 2011); and CXCL1, known to
nitiate migration of osteoclasts (Xu et al. 2010). Interestingly, while
oth the AR and BF supplemental treatments suppressed inﬂamma-
ory markers, there were no effects on these markers with the com-
ined treatment.
These results demonstrate that the two botanical extract combi-
ations developed through a targeted series of in vitro and in vivo
ssays (Lin et al. 2014) caused changes in gene expression indicat-
ng that osteoclastic and osteogenic processes were modulated with
oth. The anti-resorptive combination of pomegranate and grape
eed extracts caused differential expression of select annotated genes
elated to the reduction of bone resorption through the inhibition of
roliferation and activation of osteoclasts possibly through the inhi-
ition of the RANK-RANKL pathway. The bone formation combina-
ion of quercetin and licorice extracts demonstrated a series of dif-
erentially expressed genes known to reduce osteoclast activity and
ncrease osteoblastic activity in part through the stimulation of the
MP-2 pathway. The combination of all four plant extracts demon-
trates that modulating both bone resorption and bone formation
imultaneously is diﬃcult, possibly due to multiple feedback sys-
ems balancing the osteoblast and osteoclast activity. In summary,
his ex-vivomicroarray study indicates that the two botanical extract
ombinations modulate gene expression for both osteoclastic and os-
eogenic processes. Further work is warranted to conﬁrm these re-
ults and to investigate the effect of the botanical extracts on the dif-
erentially expressed genes and their functional relationship to bone
etabolism.
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